您要查找的是不是:
- Roles of receptor tyrosine kinases, integrins, and Shc. 外文期刊 Mechanotransduction in response to shear stress.
- The inhibitor of VEGF receptor tyrosine kinase was introduced in detail. 詳細介紹了VEGF受體酪氨酸激酶抑制劑的研究進(jìn)展。
- Sunitinb is a novel multitargeted receptor tyrosine kinase inhibitor. 蘇尼替尼是一種新型的多靶點(diǎn)酪氨酸激酶抑制劑。
- Objective.Protein tyrosine phosphatase non-receptor type 22 (PTPN22) is a member of the PTPs that negatively regulate T-cell activation. 目的:蛋白酪氨酸磷酸酶非受體型22(Protein tyrosine phosphatase non-receptor type 22,PTPN22)是T細胞激活的抑制性調節分子。
- SHP-2, a cytoplasmic SH2 domain containing protein tyrosine phosphatase is involved in the signaling pathways of a variety of growth factors and cytokines. SHP-2,一種含有SH2區域的胞漿蛋白酪氨酸磷酸酶,參與了各種生長(cháng)因子和細胞因子的信號傳導過(guò)程。
- Objective:To explore the mutation of receptor tyrosine kinase ( RET ) gene in sporadic medullary thyroid carcinoma. 目的:研究散發(fā)型甲狀腺髓樣癌酪氨酸激酶受體基因(RET)的突變情況。
- Angiopoietin acts on Tie-2,which is a receptor tyrosine kinase specifically expressed on endothelial cells. 作用于內皮特異受體酪氨酸激酶酪氨酸激酶受體2。
- We are interested in the identification of novel components in Drosophila EGF receptor tyrosine kinase (RTK) signal transduction pathway. 我們主要的興趣在于用遺傳學(xué)及分子生物學(xué)的方法來(lái)研究果蠅的胚胎發(fā)育過(guò)程。
- All these actions of VEGF are mediated by receptor tyrosine kinase, vascular endothelial growth factor receptor (VEGFR). 所有這些作用都是通過(guò)血管內皮生長(cháng)因子受體信號轉導通路實(shí)現的。
- Objective To investigate the expression level of Shp-2 tyrosine phosphatase in chronic myeloid leukemia (CML) and its relationship with the unlimited growth and apoptosis resistance of p210 bcr/abl-induced malignant cells. 目的研究Src癌基因同源的酪氨酸蛋白磷酸酶2(Shp2)在慢性粒細胞白血病(CML)細胞中的表達,及其在p210bcr/abl誘導的白血病細胞惡性增殖和凋亡抵抗中的作用。
- The outcome is the absolutely deficit of insulin in the body.Some autoantigen including insulin,glutamate decarboxylase and tyrosine phosphatase maybe targeted antigen triggering t... 一些自身抗原如胰島素、谷氨酸脫羧酶和酪氨酸磷酸酶等可能是觸發(fā)該自身免疫反應的靶抗原,而細胞因子、趨化因子及炎性介質(zhì)等亦參與了該免疫過(guò)程。
- This article reviewed classification, structure and functions of receptor tyrosine protein kinase as well as the progress of some relative cell transduction mechanisms. 本文主要介紹生長(cháng)因子受體酪氨酸蛋白激酶的分類(lèi)、結構與功能及其部分相關(guān)信號轉導機制的研究進(jìn)展。
- The 8 new mutations included three in genes that normally suppress the growth of tumor cells, one being the PTPRT tyrosine phosphatase gene, which is sometimes found mutated in colon cancer. 8個(gè)新的突變位點(diǎn)中,有3個(gè)基因通常起到抑制腫瘤細胞生長(cháng)的功能,另外一個(gè)PTPRT酪氨酸磷酸酶基因在結腸癌中會(huì )發(fā)生突變。
- The epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases have close connection with the initiation, progression and progn osis of various malignancies. 表皮生長(cháng)因子受體(EGFR)家族的受體酪氨酸激酶與多種惡性腫瘤的發(fā)生、發(fā)展及預后等密切相關(guān)。
- Receptor tyrosine kinase (RTK), a membrane receptor superfamily with intrinsic protein tyrosine kinase activity, has many members and complicated signal transduction pathways. 摘要受體酪氨酸激酶是一個(gè)具有內在酪氨酸蛋白激酶活性的膜受體超家族,成員眾多,信號轉導通路復雜多樣。
- Moreover, non-cytotoxic agents such as small molecules targeting receptor tyrosine kinases and intracellular signaling pathways have been used in the clinical field. 替莫唑胺及亞硝基脲類(lèi)藥物耐藥性得到了部分解決以及非細胞毒性藥物如酪氨酸激酶抑制劑及細胞間信號傳導通路抑制劑在臨床中的應用。
- Receptor tyrosine protein kinase is one of key kinases in cell signal transduction and plays an important role in the process of cell growth, development and functions regulated by growth factors. 受體酪氨酸蛋白激酶是細胞信號轉導進(jìn)行的關(guān)鍵信號酶,在生長(cháng)因子調控細胞生長(cháng)、發(fā)育與功能的過(guò)程中起著(zhù)重要的生理作用。
- However, the role of specific protein tyrosine phosphatases (PTPs) in these pathways is unknown. 然而,在這些途徑中,特異性酪氨酸蛋白激酶的作用尚未清楚。
- Objective To construct the antisense nucleic acid eukaryotic expressing vector of the cDNA sequence encoding the transmembrane domain of receptor tyrosine kinase RON (RON-RTK) gene (RONm). 目的構建RON基因跨膜區段(RONm)的反義核酸真核表達載體。
- Sorafenib, a novel, oral multi-kinase inhibitor, targets on serine/threonine and receptor tyrosine kinases of the tumor cells and vasculature; blocks the signal transconduction and inhibits tumor growth. 摘要索拉非尼是首個(gè)口服多激酶抑制藥,靶向作用于腫瘤細胞和腫瘤血管上的絲氨酸和(或)蘇氨酸及受體酪氨酸激酶,阻斷信號傳導,抑制腫瘤生長(cháng)。